Inotuzumab ozogamicin (solution)
Inotuzumab ozogamicin solution (CMC-544 solution) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin solution and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin solution has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin solution can be used in the research of acute lymphoblastic leukemia.
For research use only. We do not sell to patients.
- CAS No.: 635715-01-4
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P9985
Disitamab vedotin -
HY-141601
Telisotuzumab vedotin -
HY-P3239
Belantamab mafodotin -
HY-P99813
Patritumab deruxtecan -
HY-P99107A
Brentuximab vedotin (solution) -
HY-109539
Gemtuzumab ozogamicin -
HY-152963
Tisotumab vedotin -
HY-132253
Polatuzumab vedotin -
HY-P99349
Loncastuximab tesirine -
HY-P99681
Labetuzumab govitecan -
HY-P9959
Inotuzumab ozogamicin -
HY-P99683
Ladiratuzumab vedotin
Biological Activity
Description
In Vitro
Inotuzumab ozogamicin solution exerts highly potent cytotoxic activity against a vari-
ety of CD22-positive B-cell origin cancer cell lines[1].
Inotuzumab ozogamicin solution and G544
bind human CD22 with similar affinities (KD ≈ 150 pM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Chemical Information
-
CAS No. 635715-01-4
-
SMILES
[Inotuzumab ozogamicin (solution)]
-
Synonyms
CMC-544 (solution); PF-5208773 (solution); WAY-207294 (solution)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Shor B, et al. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015;67(2 Pt A):107-116. [Content Brief]
[2]. Kantarjian H, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403-411. [Content Brief]
[3]. Advani A, et al. Safety, pharmacokinetics, and preliminary clinical activity of Inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol. 2010;28(12):2085-2093. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Inotuzumab ozogamicin (solution) Related Classifications
HY-P9959A Related Classifications
Powered by Bioz
Keywords
- Inotuzumab ozogamicin (solution)
- 635715-01-4
- CMC-544 (solution)
- PF-5208773 (solution)
- WAY-207294 (solution)
- Antibody-Drug Conjugates (ADCs)
- CD22
- B-cell malignancy models
- diffuse large B-cell lymphoma
- non-Hodgkin’s lymphoma
- apoptosis
- calicheamicin
- DNA double-strand breaks
- B-cell
- follicular lymphoma
- acute lymphocytic leukemia
- Inhibitor
- inhibitor
- inhibit